Phase 3 trial end-dates
Phase 3 trial end-dates
Since we're getting close to the end of some of the phase 3 trials, I thought I'd post a summary of what we know about those trial completion dates. The list below includes only those drugs that have completed enrollment in at least 1 phase 3 trial (e.g. no MN166 on this list).
In order of trial completion:
1. cladribine (Mylinax) (RRMS)
- announced completion of enrollment of first phase 3 trial: January 16, 2007
- study completion: January 16, 2009
- submitted to US and European regulators 3Q2009, submission incomplete
- resubmitted June 2010
2. Fingolimod (FTY720) (RRMS)
- completion of enrollment of first phase 3 trial: summer 2007 (not sure exact date)
- study completion: summer 2009
- submitted to US and European regulators December 2009
- FDA committee recommends approval June 2010
3. Teriflunomide (RRMS)
- completion of enrollment of first phase 3 trial: October 2008
- study completion: October 2010
4. Laquinimod (RRMS)
- announced completion of enrollment of first phase 3 trial: November 18, 2008 and completion of enrollment of second phase 3 trial in June 2009
- study completion: November 18, 2010 / June 2011
5. Campath (alemtuzumab) (RRMS)
- announced completion of enrollment of second phase 3 trial: September 11, 2009
- study completion: September 11, 2011
6. BG00012
- 2 phase 3 trials have completed enrollment, one in January 2009, the other in September 2009
- study completion: January / September 2011
7. Cannabinoids (CUPID trial) (progressive MS)
- announced completion of enrollment of trial: July 21, 2008
- study completion: February 21, 2012 (some patients will be in trial for 3.5 years)
In order of trial completion:
1. cladribine (Mylinax) (RRMS)
- announced completion of enrollment of first phase 3 trial: January 16, 2007
- study completion: January 16, 2009
- submitted to US and European regulators 3Q2009, submission incomplete
- resubmitted June 2010
2. Fingolimod (FTY720) (RRMS)
- completion of enrollment of first phase 3 trial: summer 2007 (not sure exact date)
- study completion: summer 2009
- submitted to US and European regulators December 2009
- FDA committee recommends approval June 2010
3. Teriflunomide (RRMS)
- completion of enrollment of first phase 3 trial: October 2008
- study completion: October 2010
4. Laquinimod (RRMS)
- announced completion of enrollment of first phase 3 trial: November 18, 2008 and completion of enrollment of second phase 3 trial in June 2009
- study completion: November 18, 2010 / June 2011
5. Campath (alemtuzumab) (RRMS)
- announced completion of enrollment of second phase 3 trial: September 11, 2009
- study completion: September 11, 2011
6. BG00012
- 2 phase 3 trials have completed enrollment, one in January 2009, the other in September 2009
- study completion: January / September 2011
7. Cannabinoids (CUPID trial) (progressive MS)
- announced completion of enrollment of trial: July 21, 2008
- study completion: February 21, 2012 (some patients will be in trial for 3.5 years)
Last edited by dignan on Fri Jun 11, 2010 12:24 pm, edited 7 times in total.
- daverestonvirginia
- Family Elder
- Posts: 196
- Joined: Mon Apr 09, 2007 2:00 pm
- Location: Reston, Virginia
- Contact:
- thinkingoutloud86
- Family Elder
- Posts: 122
- Joined: Wed May 31, 2006 2:00 pm
Dignan:
That's a good question. I will ask when exactly Cladribine might be approved the next time I talk to the nurse (I'm in the CombiRX trial there, so I have to keep in touch with them).
Dr Rus' presentation at this link
http://www.umm.edu/ms/symposium_presentations.htm
has some info on Cladribine. His concluding slide shows it being approved a few years from now, but the slides might be a little dated. The other 2 presentations are pretty good, too.
That's a good question. I will ask when exactly Cladribine might be approved the next time I talk to the nurse (I'm in the CombiRX trial there, so I have to keep in touch with them).
Dr Rus' presentation at this link
http://www.umm.edu/ms/symposium_presentations.htm
has some info on Cladribine. His concluding slide shows it being approved a few years from now, but the slides might be a little dated. The other 2 presentations are pretty good, too.
Ok, I was curious, so I did a little web searching. This link has a little information about what "FDA fasttrack" means:
<shortened url>
I will still ask about the status of Cladribine when I get the chance.
Mike
<shortened url>
I will still ask about the status of Cladribine when I get the chance.
Mike